Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.
Although functional rating scales are being used increasingly as primary outcome measures in spinal muscular atrophy (SMA), sensitive and objective assessment of early-stage disease progression and drug efficacy remains challenging. We have developed a game based on the Microsoft Kinect sensor, spec...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5266257?pdf=render |
id |
doaj-064c0dc62a234960a3a91a48089cb6f7 |
---|---|
record_format |
Article |
spelling |
doaj-064c0dc62a234960a3a91a48089cb6f72020-11-25T01:07:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e017047210.1371/journal.pone.0170472Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.Xing ChenJuliane Siebourg-PolsterDetlef WolfChristian CzechUlrike BonatiDirk FischerOmar KhwajaMartin StrahmAlthough functional rating scales are being used increasingly as primary outcome measures in spinal muscular atrophy (SMA), sensitive and objective assessment of early-stage disease progression and drug efficacy remains challenging. We have developed a game based on the Microsoft Kinect sensor, specifically designed to measure active upper limb movement. An explorative study was conducted to determine the feasibility of this new tool in 18 ambulant SMA type III patients and 19 age- and gender-matched healthy controls. Upper limb movement was analysed elaborately through derived features such as elbow flexion and extension angles, arm lifting angle, velocity and acceleration. No significant differences were found in the active range of motion between ambulant SMA type III patients and controls. Hand velocity was found to be different but further validation is necessary. This study presents an important step in the process of designing and handling digital biomarkers as complementary outcome measures for clinical trials.http://europepmc.org/articles/PMC5266257?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xing Chen Juliane Siebourg-Polster Detlef Wolf Christian Czech Ulrike Bonati Dirk Fischer Omar Khwaja Martin Strahm |
spellingShingle |
Xing Chen Juliane Siebourg-Polster Detlef Wolf Christian Czech Ulrike Bonati Dirk Fischer Omar Khwaja Martin Strahm Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients. PLoS ONE |
author_facet |
Xing Chen Juliane Siebourg-Polster Detlef Wolf Christian Czech Ulrike Bonati Dirk Fischer Omar Khwaja Martin Strahm |
author_sort |
Xing Chen |
title |
Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients. |
title_short |
Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients. |
title_full |
Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients. |
title_fullStr |
Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients. |
title_full_unstemmed |
Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients. |
title_sort |
feasibility of using microsoft kinect to assess upper limb movement in type iii spinal muscular atrophy patients. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
Although functional rating scales are being used increasingly as primary outcome measures in spinal muscular atrophy (SMA), sensitive and objective assessment of early-stage disease progression and drug efficacy remains challenging. We have developed a game based on the Microsoft Kinect sensor, specifically designed to measure active upper limb movement. An explorative study was conducted to determine the feasibility of this new tool in 18 ambulant SMA type III patients and 19 age- and gender-matched healthy controls. Upper limb movement was analysed elaborately through derived features such as elbow flexion and extension angles, arm lifting angle, velocity and acceleration. No significant differences were found in the active range of motion between ambulant SMA type III patients and controls. Hand velocity was found to be different but further validation is necessary. This study presents an important step in the process of designing and handling digital biomarkers as complementary outcome measures for clinical trials. |
url |
http://europepmc.org/articles/PMC5266257?pdf=render |
work_keys_str_mv |
AT xingchen feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients AT julianesiebourgpolster feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients AT detlefwolf feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients AT christianczech feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients AT ulrikebonati feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients AT dirkfischer feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients AT omarkhwaja feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients AT martinstrahm feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients |
_version_ |
1725187479872471040 |